Targeting A-Kinase Anchoring Proteins (AKAPs) offers potential therapies for improving defective calcium cycling in cardiac myocytes.
This review highlights the critical role of AKAPs in cardiac calcium cycling and their potential as therapeutic targets for heart failure.
The rate of calcium cycling and calcium transient amplitude are critical determinants for the efficient contraction and relaxation of the heart. Calcium-handling proteins in the cardiac myocyte are altered in heart failure, and restoring the proper function of those proteins is an effective potential therapeutic strategy. The calcium-handling proteins or their regulators are phosphorylated by a cAMP-dependent kinase (PKA), and thereby their activity is regulated. A-Kinase Anchoring Proteins (AKAPs) play a seminal role in orchestrating PKA and cAMP regulators in calcium handling and contractile machinery. This cAMP/PKA orchestration is crucial for the increased force and rate of contraction and relaxation of the heart in response to fight-or-flight. Knockout models and the few available preclinical models proved that the efficient targeting of AKAPs offers potential therapies tailor-made for improving defective calcium cycling. In this review, we highlight important studies that identified AKAPs and their regulatory roles in cardiac myocyte calcium cycling in health and disease.
Subramanian et al. (Sat,) conducted a review in Heart failure. Targeting of A-Kinase Anchoring Proteins (AKAPs) was evaluated. Targeting A-Kinase Anchoring Proteins (AKAPs) offers potential therapies for improving defective calcium cycling in cardiac myocytes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: